Table 3.
Cost-effectiveness of antibiotics for treatment of pneumonia patients
| Treatment strategy | Total cost (USD) | Incremental cost (USD) | Total LY | LY saveda | ICER per LY saved |
|---|---|---|---|---|---|
| Vancomycin | 16,346 | 9.84 | |||
| Teicoplanin | 12,487 | − 3858 | 10.80 | 0.96 | Dominant |
| Linezolid | 19,230 | 2884 | 11.16 | 1.32 | 2185 |
USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio
aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin